US4970300A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Modified factor VIII
Assignee: Bayer Corp
•
Filing: 1989-01-18
•
Granted: 1990-11-13
•
Expires: 2009-01-18
Abstract
Abstract Disclosed are conjugates of a protein having antihemophilic factor (Factor VIII) activity linked to nonantigenic ligands. The conjugates have longer half life than the unconjugated protein but maintain substantial Factor VIII activity.
Inventors
- 👤 Anne J. Fulton
- 👤 Alan J. Johnson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 00:42
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/644; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/59; A61K47/60; A61K47/61; B; B01; B01J; B01J41/00; B01J41/20; C07; C07K; C07K1/00; C07K1/14; C07K1/16; C07K1/18; C07K14/00; C07K14/435; C07K14/745; C07K14/755; C07K14/76; C07K14/765; C07K16/00; C07K16/06; C07K16/065; C12N9/647; C12Y; C12Y304/00; C12Y304/21; C12Y304/21022; A61K38/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
71 words
An infusible conjugate comprising a protein having Factor VIII activity covalently linked to a nonantigenic ligand, said conjugate: being activatable by thrombin; retaining at least a substantial portion of the activity of said protein prior to conjugation; and having a sufficiently prolonged in vivo disappearance time compared to said protein in the unconjugated state to at least compensate for any loss of activity of said conjugate compared to said unconjugated protein.
Claim 2
Dependent Claim
71 words
An infusible conjugate comprising a protein having Factor VIII activity covalently linked to a nonantigenic ligand, said conjugate: being activatable by thrombin; retaining at least a substantial portion of the activity of said protein prior to conjugation; and having a sufficiently prolonged in vivo disappearance time compared to said protein in the unconjugated state to at least compensate for any loss of activity of said conjugate compared to said unconjugated protein.
Claim 3
Dependent Claim
52 words
The conjugate of claim 1 wherein said ligand is selected from the group consisting of polysaccharides, sialic acid, albumin, von Willebrand factor, glycopeptides containing sialic acid available for coupling, polyethylene glycols wherein said ethylene is substituted or unsubstituted, poly(vinylpyrrolidone), poly D + alanine, poly D + glutamine and poly D + lysine.
Claim 4
Dependent Claim
11 words
The conjugate of claim 1 wherein said ligand is a polysaccharide.
Claim 5
Dependent Claim
10 words
The conjugate of claim 3 wherein said ligand is dextran.
Claim 6
Dependent Claim
21 words
The conjugate of claim 1 wherein said protein is selected from the group consisting of native and recombinant mammalian Factor VIII.
Claim 7
Dependent Claim
15 words
The conjugate of claim 1 wherein said ligand is a substituted or unsubstituted polyethylene glycol.
Claim 8
Dependent Claim
44 words
The conjugate of claim 1 wherein said conjugate is formed using a member selected from the group consisting of trichloro-s-triazine, dichloro-s-triazine, monochloro-s-triazine, 1,1'carboaryldiimidazole, hydroxysuccinimide, monofunctional or bi-functional cross-linking agents, cyanogen bromide and sodium periodate, as the linking agent between said protein and said ligand.
Claim 9
Dependent Claim
19 words
The conjugate of claim 7 wherein said linking agent is sodium periodate and said ligand is nonantigenic, nonanticoagulant dextran.
Claim 10
Dependent Claim
28 words
The conjugate of claim 8 wherein said protein is selected from the group of manmmalian native and recombinant human antihemophilic factor and fragments thereof having antihemophilic factor activity.
Claim 11
Dependent Claim
57 words
The conjugate of claim 1 wherein said protein has been purified from a partially purified preparation of said protein by column chromatography using a positively charged ionic group on a solid-phase support as the adsorbent and a loading and washing buffer containing 0.05-2.0 M of a carbohydrate selected from the group consisting of glucose, sorbitol and lactose.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-11-12 | 1994-05-14 | 1994-11-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-11-12 | 1998-05-14 | 1998-11-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-11-12 | 2002-05-14 | 2002-11-13 | $7700.00 | Window Closed / Lapsed |